AGIO vs. CPRX, GLPG, ZLAB, PTGX, RCKT, KROS, EVO, AMPH, ARDX, and AMRX
Should you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Catalyst Pharmaceuticals (CPRX), Galapagos (GLPG), Zai Lab (ZLAB), Protagonist Therapeutics (PTGX), Rocket Pharmaceuticals (RCKT), Keros Therapeutics (KROS), Evotec (EVO), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical preparations" industry.
Agios Pharmaceuticals (NASDAQ:AGIO) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Agios Pharmaceuticals currently has a consensus price target of $35.00, indicating a potential downside of 7.89%. Catalyst Pharmaceuticals has a consensus price target of $26.71, indicating a potential upside of 68.23%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Agios Pharmaceuticals.
Agios Pharmaceuticals has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.
Catalyst Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Catalyst Pharmaceuticals received 5 more outperform votes than Agios Pharmaceuticals when rated by MarketBeat users. Likewise, 74.31% of users gave Catalyst Pharmaceuticals an outperform vote while only 67.51% of users gave Agios Pharmaceuticals an outperform vote.
Catalyst Pharmaceuticals has a net margin of 15.83% compared to Agios Pharmaceuticals' net margin of -1,199.26%. Catalyst Pharmaceuticals' return on equity of 25.08% beat Agios Pharmaceuticals' return on equity.
79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 4.9% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Agios Pharmaceuticals had 13 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 4 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.31 beat Agios Pharmaceuticals' score of 0.55 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.
Summary
Catalyst Pharmaceuticals beats Agios Pharmaceuticals on 16 of the 18 factors compared between the two stocks.
Get Agios Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agios Pharmaceuticals Competitors List
Related Companies and Tools
